These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 23831532

  • 1. Evaluation of neuropeptide loaded trimethyl chitosan nanoparticles for nose to brain delivery.
    Kumar M, Pandey RS, Patra KC, Jain SK, Soni ML, Dangi JS, Madan J.
    Int J Biol Macromol; 2013 Oct; 61():189-95. PubMed ID: 23831532
    [Abstract] [Full Text] [Related]

  • 2. Preparation and evaluation of anti-neuroexcitation peptide (ANEP) loaded N-trimethyl chitosan chloride nanoparticles for brain-targeting.
    Wang S, Jiang T, Ma M, Hu Y, Zhang J.
    Int J Pharm; 2010 Feb 15; 386(1-2):249-55. PubMed ID: 19900520
    [Abstract] [Full Text] [Related]

  • 3. Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system.
    Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W.
    J Control Release; 2006 Mar 10; 111(1-2):107-16. PubMed ID: 16380189
    [Abstract] [Full Text] [Related]

  • 4. TMC-MCC (N-trimethyl chitosan-mono-N-carboxymethyl chitosan) nanocomplexes for mucosal delivery of vaccines.
    Sayin B, Somavarapu S, Li XW, Sesardic D, Senel S, Alpar OH.
    Eur J Pharm Sci; 2009 Nov 05; 38(4):362-9. PubMed ID: 19733658
    [Abstract] [Full Text] [Related]

  • 5. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery.
    Yin L, Ding J, He C, Cui L, Tang C, Yin C.
    Biomaterials; 2009 Oct 05; 30(29):5691-700. PubMed ID: 19615735
    [Abstract] [Full Text] [Related]

  • 6. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen.
    Slütter B, Bal S, Keijzer C, Mallants R, Hagenaars N, Que I, Kaijzel E, van Eden W, Augustijns P, Löwik C, Bouwstra J, Broere F, Jiskoot W.
    Vaccine; 2010 Aug 31; 28(38):6282-91. PubMed ID: 20638455
    [Abstract] [Full Text] [Related]

  • 7. Lipophilic derivatives of leu-enkephalinamide: in vitro permeability, stability and in vivo nasal delivery.
    Cros CD, Toth I, Blanchfield JT.
    Bioorg Med Chem; 2011 Feb 15; 19(4):1528-34. PubMed ID: 21273080
    [Abstract] [Full Text] [Related]

  • 8. Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation.
    Paliwal R, Paliwal SR, Agrawal GP, Vyas SP.
    Int J Pharm; 2012 Jan 17; 422(1-2):179-84. PubMed ID: 22079712
    [Abstract] [Full Text] [Related]

  • 9. Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization.
    Shahnaz G, Vetter A, Barthelmes J, Rahmat D, Laffleur F, Iqbal J, Perera G, Schlocker W, Dünnhaput S, Augustijns P, Bernkop-Schnürch A.
    Int J Pharm; 2012 May 30; 428(1-2):164-70. PubMed ID: 22421322
    [Abstract] [Full Text] [Related]

  • 10. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease.
    Meng Q, Wang A, Hua H, Jiang Y, Wang Y, Mu H, Wu Z, Sun K.
    Int J Nanomedicine; 2018 May 30; 13():705-718. PubMed ID: 29440896
    [Abstract] [Full Text] [Related]

  • 11. Covalently stabilized trimethyl chitosan-hyaluronic acid nanoparticles for nasal and intradermal vaccination.
    Verheul RJ, Slütter B, Bal SM, Bouwstra JA, Jiskoot W, Hennink WE.
    J Control Release; 2011 Nov 30; 156(1):46-52. PubMed ID: 21784113
    [Abstract] [Full Text] [Related]

  • 12. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
    Fazil M, Md S, Haque S, Kumar M, Baboota S, Sahni JK, Ali J.
    Eur J Pharm Sci; 2012 Aug 30; 47(1):6-15. PubMed ID: 22561106
    [Abstract] [Full Text] [Related]

  • 13. Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain.
    Hanafy AS, Farid RM, ElGamal SS.
    Drug Dev Ind Pharm; 2015 Aug 30; 41(12):2055-68. PubMed ID: 26133084
    [Abstract] [Full Text] [Related]

  • 14. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
    Sayin B, Somavarapu S, Li XW, Thanou M, Sesardic D, Alpar HO, Senel S.
    Int J Pharm; 2008 Nov 03; 363(1-2):139-48. PubMed ID: 18662762
    [Abstract] [Full Text] [Related]

  • 15. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
    Amidi M, Romeijn SG, Verhoef JC, Junginger HE, Bungener L, Huckriede A, Crommelin DJ, Jiskoot W.
    Vaccine; 2007 Jan 02; 25(1):144-53. PubMed ID: 16973248
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain.
    Wang ZH, Wang ZY, Sun CS, Wang CY, Jiang TY, Wang SL.
    Biomaterials; 2010 Feb 02; 31(5):908-15. PubMed ID: 19853292
    [Abstract] [Full Text] [Related]

  • 19. Evaluation and modification of N-trimethyl chitosan chloride nanoparticles as protein carriers.
    Chen F, Zhang ZR, Huang Y.
    Int J Pharm; 2007 May 04; 336(1):166-73. PubMed ID: 17145144
    [Abstract] [Full Text] [Related]

  • 20. Brain delivery of buspirone hydrochloride chitosan nanoparticles for the treatment of general anxiety disorder.
    Bari NK, Fazil M, Hassan MQ, Haider MR, Gaba B, Narang JK, Baboota S, Ali J.
    Int J Biol Macromol; 2015 Nov 04; 81():49-59. PubMed ID: 26210037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.